| To investigate the clinical efficacy of HBsAg positive donor liver in liver transplantation. Methods Clinical data of 17 patients undergoing liver transplantation with HBsAg positive liver donor in Beijing You’an Hospital from March 2006 to May 2021 were analyzed retrospectively. The postoperative antiviral therapy and anti-rejection therapy, prognosis, serological and viral load changes of postoperative HBV infection were summarized. Results Among the 17 patients, 15 cases had primary liver cancer and 2 cases had liver failure. All patients were treated with hepatitis B immunoglobulin during perioperative period and oral nucleoside drugs as anti-HBV therapy after operation. One patient with liver cancer died of septic shock during perioperative period, and 7 patients with liver cancer died of liver cancer recurrence within 5-64 months after operation. The longest survival time of patients with liver cancer was 143 months (still alive until the completion of this paper), and the longest survival time of patients with liver failure was 184 months (still alive until the completion of this paper). All patients were HBsAg positive after operation, long-term survivors had normal liver function, and there was no cirrhosis or graft dysfunction caused by HBV infection. Conclusions On the premise of accurate evaluation and screening of donors, it is safe and feasible to use HBsAg positive liver donor for liver transplantation, especially for those with liver failure and other urgent life-threatening events for liver transplantation. Patients with benign liver disease can also obtain long-term survival after operation. However, it is necessary to use potent and high gene barrier anti-HBV drugs, perform HBV monitoring and follow-up management, and closely observe the complications of long-term survivors. |